Status: Not yet recruiting
Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
This is an open-label, prospective, single-arm, multicenter study designed to evaluate the efficacy and safety of MTX plus pirtobrutinib combined with routinely-used clinical chemoimmunotherapy regimens in patients with DLBCL and central nervous system (CNS) involvement.
Participants needed: 24
Trial details
Phase: Phase 2Age: 14-80Biological sex: AllType: InterventionalSponsor: Pengpeng XuUpdated: Sep 11, 2026Locations: 1
Eligibility criteria
Bone marrow function: absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L; platelet co... [+4]
Contraindication to any drug in the treatment regimen. [+6]